Moderna’s Shares Gain in Premarket as New Flu Shot Shows Promising Results

Moderna Inc. (MRNA) shares surged 5.49% in premarket trading on Monday, June 30, 2025, following the biotechnology company’s announcement of positive Phase 3 trial results for its experimental mRNA-based influenza vaccine.

The stock climbed to $28.65 in premarket trading after closing at $27.16 the previous session, marking a significant bounce for shares that have declined over 30% year-to-date. The promising trial data not only paves the way for Moderna’s standalone flu vaccine approval but also clears a crucial regulatory hurdle for the company’s combination COVID-19 and influenza shot.

Moderna Study Results Drive Stock Gains in Premarket Trading

Moderna’s experimental mRNA-based flu vaccine, designated mRNA-1010, demonstrated significant superiority over currently available influenza vaccines in a comprehensive Phase 3 trial involving over 40,000 adults aged 50 and above.

The study revealed that Moderna’s shot was 26.6% more effective than standard competitor vaccines in the overall study population, with even stronger results among adults aged 65 and older, showing 27.4% greater efficacy. The vaccine demonstrated robust performance across all major influenza strains included in the shot, including A/H1N1, A/H3N2, and B/Victoria lineages.

This breakthrough positions Moderna as the apparent frontrunner against competitors Pfizer (NYSE: PFE) and Novavax (NASDAQ: NVAX) in developing next-generation influenza vaccines.

Join our Telegram group and never miss a breaking digital asset story.

MRNA Stock: Premarket Surge Amid Challenging Year

MRNA stock demonstrated strong premarket momentum on Monday, gaining $1.49 to reach $28.65, representing a 5.49% increase from the previous close of $27.16. The premarket surge occurred at 7:29:59 AM EDT, showing significant early investor enthusiasm for the trial results.

Despite this positive movement, Moderna shares remain under pressure for 2025, declining 34.68% year-to-date compared to the S&P 500’s 4.96% gain during the same period.

The stock’s recent performance reflects broader challenges facing the biotechnology company, including regulatory uncertainties and reduced COVID-19 vaccine demand.

Key financial metrics highlight the company’s current struggles, with a negative profit margin of 105.67%, return on equity of -29.34%, and diluted earnings per share of -$8.73.

However, Moderna maintains a strong balance sheet with $5.98 billion in total cash and relatively low debt levels, providing financial flexibility during this transitional period.

Analyst sentiment remains mixed, with price targets ranging from $20.00 to $198.00 and an average target of $47.59, suggesting potential upside from current levels. The company’s market capitalization stands at $10.504 billion, reflecting its position as a significant player in the biotechnology sector despite recent operational challenges.

The positive flu vaccine data could serve as a catalyst for improved investor confidence, particularly as Moderna seeks to diversify its revenue streams beyond COVID-19 vaccines into broader respiratory and infectious disease markets.

Disclaimer: The author does not hold or have a position in any securities discussed in the article. All stock prices were quoted at the time of writing.